

LabCorp Specialty Testing Group

One Forest Parkway • Shelton, CT 06484
203-926-7100 • 800-328-2666 • www.dianon.com

CLIENT INFORMATION

REQUESTING PHYSICIAN	NPI#
REFERRING PHYSICIAN	NPI#

BILLING INFORMATION (face sheet & front and back of insurance card must be attached)

Bill: My Account Insurance Medicare Medicaid Patient Workers Comp

Patient Status: Hospital Inpatient Hospital Outpatient Non-Hospital Patient

Insurance Information: See attached

Insured Information: Name _____

Relationship to Patient (circle one) Self Spouse Child Other: _____

Primary Insurance Co: _____ Authorization # _____

Billing Address _____ Insured # _____

Billing City, State, Zip _____ Group # _____

Secondary Insurance Co: _____ Authorization # _____

Billing Address _____ Insured # _____

Billing City, State, Zip _____ Group # _____

PATIENT INFORMATION

Name (LAST, FIRST, MIDDLE) _____

Address _____

City, State, Zip _____

Date of Birth: MM / DD / YYYY _____

Sex M F

Phone Number _____

Race: _____

MRN / PATIENT ID # _____

Chart # _____

Physician/Authorized Signature: _____

CLINICAL INFORMATION

Collection Date: MM / DD / YYYY Time: _____ A.M. P.M.

Number of Jars: _____

All diagnoses should be provided by the ordering physician or his or her authorized designee.
Diagnosis/Signs/Symptoms in ICD-CM format in effect at Date of Service (Highest Specificity Required)

REQUIRED INFORMATION	ICD-CM		ICD-CM	
ICD-CM		ICD-CM		ICD-CM

HISTOLOGY † Separately billable stains may be added by pathologist when medically necessary to render a diagnosis.

H&E Histology (Gross & Microscopic) †

H&E Histology (Gross & Microscopic) † Reflex to Melanoma FISH panel (K700D#) on histologically borderline lesions¹ (see back)

(D9F-1) Direct Immunofluorescence (IgA, IgG, IgM, C3) (Michel's Media)

(D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fibrinogen, IgA, IgG, IgM, C3) (Michel's Media)

BRAF Gene Mutation Assay, Melanoma (481110) (send pathology report) 81210, 88381

Consultation: On referred slides † (send pathology report) 88321

Consultation: Referred material requiring slide prep † (send pathology report) 88323

Histology Technical Component TC Stains _____

BIOPSY DATA (please identify anatomic site below and apply appropriate label to jar)

Jar #	Body Site/Descriptor	Specimen Type (biopsy, excision)	Clinical Data	Signs & Symptoms (see below for code)
1				
2				
3				
4				
5				
6				

Signs and Symptoms (DO NOT CIRCLE. Write in applicable number for each corresponding specimen in the area provided above.)

- | | | | | | | |
|-----------------------|----------------------|-----------------|------------------------|----------------------|--------------------|----------------------|
| 1. Cyst | 6. Plaque | 11. Annular | 16. Gyrate/Serpiginous | 21. Pain | 26. Purpura | 31. Debridement |
| 2. Keratosis | 7. Scar | 12. Atrophy | 17. Hair Loss/Alopecia | 22. Papule | 27. Pustule | 32. Soft Tissue Mass |
| 3. Nodule | 8. Scar/reexcision | 13. Bullae | 18. Hyperpigmentation | 23. Photodistributed | 28. Telangiectasia | 33. Other: |
| 4. Papule | 9. Subcutaneous Mass | 14. Erythema | 19. Hypopigmentation | 24. Plaque | 29. Vesicle | |
| 5. Pigmented Neoplasm | 10. Tag | 15. Excoriation | 20. Macule | 25. Pruritus | 30. Ulcer | |

MICROBIOLOGY

008649 Aerobic Bacterial Culture, General CPT 87070
008482 Fungus (Mycology) Culture CPT 87101
008573 Viral Culture, General CPT 87252
 Other: _____

ID and Susceptibility at additional charges per organism if indicated.

Additional Clinical History: _____

When ordering tests for which Medicare or Medicaid reimbursement will be sought, physicians should only order tests that are medically necessary for the diagnosis or treatment of the patient. Dianon Pathology is a brand of Dianon Systems, Inc., a wholly-owned subsidiary of Laboratory Corporation of America® Holdings

1190L Rev. 11/23/2016 CT Lic # CL-0356

© 2016 Laboratory Corporation of America® Holdings. All rights reserved.

Patient, Client and Billing Information is requested for timely processing of this case. Medicare and other third party payors require that services be medically necessary for coverage, and generally do not cover routine screening tests.
= Medicare deems investigational. Medicare does not pay for services it deems investigational.
Refer to Determining Necessity of ABN Completion on Reverse

SPECIMEN LABEL INSTRUCTIONS:

- Complete the requisition with all requested information.
- Remove the required number of labels from the front of this sheet.
- Place one (1) label on each specimen container (not on the lid).

PLEASE DISPOSE OF UNUSED LABELS.

AREA:	AREA:	AREA:	AREA:
AREA:	AREA:	AREA:	AREA:
AREA:	AREA:	AREA:	AREA:
TECHNICAL COMPONENT	AREA:	AREA:	AREA:

Test Combination/Panel Policy

LabCorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the LabCorp request form. LabCorp encourages clients to contact their local LabCorp representative or LabCorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all LabCorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. LabCorp will process the specimen for a Microbiology test based on source.

DEFINITIONS

1 - Borderline lesions are characterized by atypical melanocytic tumors that do not display clear-cut features of malignancy; this includes those lesions showing some resemblance to Spitz nevi, blue nevi, deep penetrating nevi, and possible nevoid melanomas.

Determining Necessity of Advance Beneficiary Notice of Noncoverage (ABN) Completion*

- 1. Diagnose.** Determine your patient's diagnosis.
- 2. Document.** Write the diagnosis code(s) on the front of this requisition.
- 3. Verify.** Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or www.LabCorp.com/MedicareMedicalNecessity.
- 4. Review.** If the diagnosis code for your patient **does not** meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.

*An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.

How to Complete an Advance Beneficiary Notice of Noncoverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, LabCorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

1. Be executed on the CMS approved ABN form (CMS-R-131)
2. Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card
3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column
4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN
5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary
6. Be signed **and** dated by the beneficiary or his/her representative **prior to** the service being rendered

CPT Codes:

Direct Immunofluorescence (IgA, IgG, IgM, C3)	88346, 88350x3
Direct Immunofluorescence (Fibrinogen, IgA, IgG, IgM, C3)	88346, 88350x4

